Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial - Concepedia

Concepedia

Publication | Open Access

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial

DOI Full Paper Access

48

Citations

20

References

2020

Year

Lawrence Blonde, Lidia Belousova, Udi Fainberg, Pedro Alberto García-Hernández, Sunil Jain, Margit S. Kaltoft, Ofri Mosenzon, Jalal Nafach, Mads Sundby Palle, Rosângela Réa

Diabetes Obesity and Metabolism

Abstract

Liraglutide significantly improved glycaemic control compared with placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings.

References

	Year	Citations

Page 1